Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 | Acetylclonidine 0.5% eye drops | ||
 | Acetylcysteine 10% eye drops | ||
| Aflibercept (Eylea®) injection |
| |
| Apraclonidine 1% eye drops (preserv-free) | Only PF sympathomimetic | |
| Balanced slat solution | Theatre use | |
| Bevacizumab (Avastin®) injection | ||
| Brolucizumab (Beovu®) | ||
 | Carmellose (Xailin fresh) | ||
| Carmellose 1% multi (Moorfields) | ||
| Ciclosporin (Ikervis) | ||
| Ciclosporin 2mg/g eye ointment (Optimmune) | ||
| Clinitas® | Non bak | |
| Diclofenac sodium - Voltarol® Ophtha multidose | ||
| Disodium edetate 0.37% (EDTA) | For hospital use only | |
| Flourescein sodium 10% injection (10 x 5ml amps) | ||
| Fluorescein sodium Minims | ||
| Hypromellose 0.5% eye drops | ||
| Ilube eye drops (10ml) (with preserv) | ||
| Ketorolac eye drops | ||
| Liquid paraffin (VitA-POS®) | Second line | |
| Liquid paraffin (Xailin® night) | ||
| Mercaptamine 0.11% eye drops | Unlicensed | |
| Mercaptamine 0.55% eye drops | Unlicensed | |
| Ocriplasmin (Jetrea®) injection | For hospital use only | |
| Ranibizumab injection | ||
| Sodium chloride 0.9% Minims | Dilutant for impregnated viral DYD strips | |
| Sodium chloride 5% eye ointment | Specialist ophthalmologist recommendation | |
| Sodium chloride preservative free 5% eye drops | Specialist ophthalmologist recommendation | |
| Sodium hyaluronate | Sodium hyaluronateviscoelastic (CIMA OCU + 1.4%- Ocuplus) | |
| Sodium hyaluronate 0.15% multi (Hyabak®) | Specialist ophthalmologist recommendation | |
| Sodium hyaluronate 0.2% eye drops P/F (Evolve HA®) | Specialist ophthalmologist recommendation | |
| Sodium hyaluronate 0.4% single-dose eye drops (20) | Specialist ophthalmologist recommendation. Sodium hyaluronate 0.4% unit dose (SDU) (Clinitas) - each unit is resealable and may be used for up to 12 hours. | |
| Verteprofin (Visudyne) | ||
| Viscotears eye drops | Liquid gel. Single dose units. High relative cost. | |
| Xailin® |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
